OpenNeedle Ask your own

Question explored with the scientific record

Does amlodopine 10mg/day have any effect on the levels of anything in the body?

Nov 20, 2026 · 5 sources used · OpenNeedle synthesis
Amlodipine 10 mg does change measurable things in the body, but the biggest one is a side effect, not a benefit.

The clearest dose-response in these records is swelling. In a 4-week trial of 240 newly diagnosed hypertensive patients, peripheral edema rose with dose: 7.5% at 2.5 mg, 13.75% at 5 mg, and 28.75% at 10 mg [2]. Moderate and severe edema clustered in the 10 mg group [2]. That is the number to weigh before you accept the top dose.

MeasureWhat changedSource
Peripheral edema28.75% at 10 mg vs 13.75% at 5 mg[2]
Oxidative stress marker (8iPGF2α)Fell after 16 weeks of amlodipine[1]
sVCAM-1 (endothelial marker)Decreased[1]
sICAM-1Initially fell, then exceeded baseline by 16 weeks[1]
sE-selectinRose; borderline in amlodipine (p=0.052)[1]
Renal blood flowInulin clearance +13%, PAH clearance +19%[4]
Serum potassiumFell about 0.2 mEq/L[4]

The endothelial markers moved in different directions, not uniformly better [1]. The renal changes came from a small 1987 study at a mean dose near 9 mg [4]. One trial found amlodipine did not significantly shrink heart muscle thickness over 16 weeks [5]. The 10 mg dose lowers blood pressure more than 5 mg [3], but the retrieved studies do not show that extra drop translates into fewer heart attacks or deaths.

My call: 10 mg measurably lowers blood pressure and shifts several lab markers, but it also roughly doubles the swelling risk versus 5 mg, and nothing here proves the higher dose buys you a hard outcome. Ask whether 5 mg plus a second drug gets the same pressure with less edema. Confidence: moderate.

Keep digging

Sources used 5

  1. Blood Pressure Reduction is Associated With the Changes in Oxidative Stress and Endothelial Activation in Hypertension, Regardless of Antihypertensive Therapy Kidney and Blood Pressure Research (2016) primary study Strong

    In newly diagnosed hypertension, 16 weeks of amlodipine or olmesartan lowered blood pressure and 8iPGF2α similarly, while soluble endothelial markers changed divergently; vitamin C/E had only a minor oxidative-stress effect.

    DOI: 10.1159/000450562
  2. Comparison of peripheral edema in patient taking 2.5mg, 5mg versus 10mg Amlodipine for hypertension in AIMS Hospital Muzaffarabad AJK Physical Education, Health and Social Sciences (2025) primary study Strong

    In hypertensive patients, higher amlodipine doses were associated with increased incidence and severity of peripheral edema, highest at 10 mg and lowest at 2.5 mg.

    DOI: 10.63163/jpehss.v3i2.386
  3. The Phase III, double-blind, parallel-group controlled study of amlodipine 10 mg once daily in Japanese patients with essential hypertension who insufficiently responded to amlodipine 5 mg once daily Journal of Human Hypertension (2009) Thin

    This Phase III double-blind study demonstrated that amlodipine 10 mg once daily is superior to amlodipine 5 mg once daily in reducing blood pressure in Japanese patients with essential hypertension who did not adequately respond to the lower dose.

    DOI: 10.1038/jhh.2008.161
  4. Amlodipine Therapy Corrects Renal Abnormalities Encountered in the Hypertensive State American Journal of Kidney Diseases (1987) Thin

    This study investigates the effects of amlodipine therapy on renal function in patients with essential hypertension, demonstrating significant improvements in glomerular filtration rate and renal plasma flow without adverse changes in body fluid composition.

    DOI: 10.1016/s0272-6386(87)80191-9
  5. Effects of Losartan Titrated to Losartan/Hydrochlorothiazide and Amlodipine on Left Ventricular Mass in Patients with Mild-to-Moderate Hypertension Cardiology (1999) primary study Strong

    In a double-blind RCT in 25 patients with mild-to-moderate essential hypertension, Losartan titrated to Losartan/HCT reduced left ventricular mass and LVM index at 16 weeks, while Amlodipine did not significantly; between-group LVM reduction favored Losartan.

    DOI: 10.1159/000006957

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question →